ログイン 会員登録
icon_bulk_order一括注文 Acrobiosystems for English
A B C D E F G H I J K L M N O P Q R S T U V W X Y Z 0-9
phone
Your Position: ホーム > LAIR-1

LAIR-1

概要

Name:Leukocyte-associated immunoglobulin-like receptor 1
Target Synonym:Immunoglobulin Heavy Chain Variable Region,HLAIR1,LAIR1,Leukocyte Associated Immunoglobulin Like Receptor 1,CD305 Antigen,hLAIR1,CD305,Leukocyte-Associated Ig-Like Receptor 1
Number of Launched Drugs:0
Number of Drugs in Clinical Trials:2
Lastest Research Phase:Phase 2 Clinical

製品リスト製品比較と製品注文

ACRO Quality

生物活性データの一部

LA1-H82F5-ELISA
 LAIR-1 ELISA

Immobilized Native Human Collagen I protein at 10 μg/mL (100 μL/well) can bind Biotinylated Human LAIR-1, Fc,Avitag (Cat. No. LA1-H82F5) with a linear range of 0.01-0.625 μg/mL (QC tested).

LA1-M52H3-MALS-HPLC
LAIR-1 MALS images

The purity of Mouse LAIR1 Protein, His Tag (Cat. No. LA1-M52H3) is more than 90% and the molecular weight of this protein is around 20-28 kDa verified by SEC-MALS.

Synonym Name

LAIR1,CD305

Background

Leukocyte-associated immunoglobulin-like receptor-1 (LAIR-1) is constitutively expressed on the majority of human peripheral blood mononuclear leukocytes. LAIR-1 or CD305 is a transmembrane glycoprotein with a single immunoglobulin-like domain and a cytoplasmic tail containing two immune receptor tyrosine-based inhibitory motifs. LAIR-1 recruits SHP-1 and SHP-2 phosphatases upon activation, and cross-linking of the LAIR-1 antigen on natural killer (NK) cells results in strong inhibition of NK cell–mediated cytotoxicity. Functions as an inhibitory receptor that plays a constitutive negative regulatory role on cytolytic function of natural killer (NK) cells, B-cells and T-cells. Activation by Tyr phosphorylation results in recruitment and activation of the phosphatases PTPN6 and PTPN11. It also reduces the increase of intracellular calcium evoked by B-cell receptor ligation.Diseases associated with LAIR1 include Chronic Active Epstein-Barr Virus Infection and Palindromic Rheumatism.

Clinical and Translational Updates

臨床試験情報

Name Research Code Research Phase Company Indications Clinical Trials
NGM-438 NGM-438 Phase 1 Clinical Merck & Co Inc, Ngm Biopharmaceuticals Inc Ovarian Neoplasms; Solid tumours; Esophageal Neoplasms; Stomach Neoplasms; Carcinoma, Renal Cell; Squamous Cell Carcinoma of Head and Neck; Pancreatic Neoplasms; Carcinoma, Transitional Cell; Mesothelioma; Cholangiocarcinoma; Breast Neoplasms; Prostatic Neoplasms; Colorectal Neoplasms; Carcinoma, Non-Small-Cell Lung; Uterine Cervical Neoplasms; Melanoma Details
NC-410 NC-410 Phase 2 Clinical Nextcure Inc Ovarian Neoplasms; Solid tumours; Stomach Neoplasms; Colorectal Neoplasms Details
NGM-438 NGM-438 Phase 1 Clinical Merck & Co Inc, Ngm Biopharmaceuticals Inc Ovarian Neoplasms; Solid tumours; Esophageal Neoplasms; Stomach Neoplasms; Carcinoma, Renal Cell; Squamous Cell Carcinoma of Head and Neck; Pancreatic Neoplasms; Carcinoma, Transitional Cell; Mesothelioma; Cholangiocarcinoma; Breast Neoplasms; Prostatic Neoplasms; Colorectal Neoplasms; Carcinoma, Non-Small-Cell Lung; Uterine Cervical Neoplasms; Melanoma Details
NC-410 NC-410 Phase 2 Clinical Nextcure Inc Ovarian Neoplasms; Solid tumours; Stomach Neoplasms; Colorectal Neoplasms Details

This web search service is supported by Google Inc.

totopphone